drugset

drugset / Trial / NCT03763253

Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms

NCT03763253 ↗

Phase 2 Active not recruiting 433 enrolled Imperial College London Wellcome Trust · collab

RandomizedFactorialOpen-labelTreatment

Summary

Local cytoreductive treatments for men with newly diagnosed metastatic prostate cancer in addition to standard of care treatment

Timeline

Start: 2019-04-10
Primary completion: 2026-08-31
Completion: 2027-01-31

Publications

Connor MJ, Shah TT, Smigielska K, Day E, Sukumar J, Fiorentino F, Sarwar N, Gonzalez M, Falconer A, Klimowska-Nassar N, Evans M, Naismith OF, Thippu Jayaprakash K, Price D, Gayadeen S, Basak D, Horan G, McGrath J, Sheehan D, Kumar M, Ibrahim A, Brock C, Pearson RA, Anyamene N, Heath C, Shergill I, Rai B, Hellawell G, McCracken S, Khoubehi B, Mangar S, Khoo V, Dudderidge T, Staffurth JN, Winkler M, Ahmed HU. Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial. BMJ Open. 2021 Feb 25;11(2):e042953. doi: 10.1136/bmjopen-2020-042953.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Abiraterone acetate	Small molecule	—	—
Background	Docetaxel	Small molecule	—	—
Background	Enzalutamide	Other / unclassified	—	—

Indications